Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | President | August 03, 2023 | August 07, 2023 |
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | May 30, 2024 | June 03, 2024 |
| Hemab Therapeutics Holdings, Inc.COAG · Entity 4476 | Director | April 30, 2026 | April 30, 2026 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Director · President of R&D | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date August 03, 2023 · Filed August 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,774 |
Ending reported balance
After 2023-08-04 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2023-08-03 · Grant · Acquired 5,082 · Balance 22,972 F1: On February 26, 2020, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2019 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company. Row 2 · 2023-08-03 · Grant · Acquired 3,859 · Balance 26,831 F2: On February 24, 2021, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2020 year-end compensation review. The PSUs vest in separate installments based on the achievement of four specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-quarter of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company. Row 3 · 2023-08-04 · Sale · Disposed 771 · Balance 26,060 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.01 to $185.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2023-08-04 · Sale · Disposed 1,869 · Balance 24,191 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.02 to $186.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2023-08-04 · Sale · Disposed 1,107 · Balance 23,084 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $186.03 to $187.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2023-08-04 · Sale · Disposed 101 · Balance 22,983 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $187.04 to $188.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2023-08-04 · Sale · Disposed 17 · Balance 22,966 F8: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $188.14 to $189.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2023-08-04 · Sale · Disposed 192 · Balance 22,774 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 515 |
Reported balance
Holding disclosure · report date 2023-08-03 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 515 F10: Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 26, 2020, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2019 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company.
F2: On February 24, 2021, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2020 year-end compensation review. The PSUs vest in separate installments based on the achievement of four specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-quarter of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company.
F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.01 to $185.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.02 to $186.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $186.03 to $187.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $187.04 to $188.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $188.14 to $189.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
Editas Medicine, Inc.
Report date May 30, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2034-05-29 | Direct | 25,000 |
Reported balance
After 2024-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025.
Hemab Therapeutics Holdings, Inc.
Report date April 30, 2026 · Filed April 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2034-05-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-30 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The warrant was granted on May 8, 2024. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2024 through January 1, 2027. |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2036-01-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrant was granted on May 8, 2024. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2024 through January 1, 2027.
F2: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
Scholar Rock Holding Corp
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 630,542 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Sale · Disposed 12,246 · Balance 630,542 F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2: Consists of 58,521 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date.
F2: Consists of 58,521 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2022 Filed Jun 21, 2022 21:04 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001104659-22-073038 · tm2218901-8_4seq1.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the first anniversary following the date of grant subject to continued service to the Issuer through such date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0001415889-22-006492 · form4-06132022_040621.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022 and is scheduled to vest in full on June 9, 2023. Read SEC document |
| May 26, 2022 Filed May 27, 2022 20:35 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001104659-22-065958 · tm2216969-8_4seq1.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2032-05-26 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting subject to continued service to the Issuer through such date. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 29,842 | $0.00 Strike: $147.47 | $0.00 |
DisclosureSEC source: 0001735276-22-000034 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,842 Underlying: Common Stock · 29,842 shares Expires 2032-02-22 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2021. The reporting person also received 15,936 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 22,380 | $0.00 Strike: $169.58 | $0.00 |
DisclosureSEC source: 0001735276-22-000005 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,380 Underlying: Common Stock · 22,380 shares Expires 2031-12-30 F1 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 303 | $195.11 | $59,118.33 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 21 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,215 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. F5 · price: Sale prices ranged from $194.82 to $195.43. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 145 | $193.67 | $28,082.15 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 20 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,518 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 126 | $193.37 | $24,364.62 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 19 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,663 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 73 | $192.25 | $14,034.25 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 18 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,789 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,000 | $191.45 | $191,450.00 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 17 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,862 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. F4 · price: Sale prices ranged from $191.14 to $191.80. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 125 | $190.86 | $23,857.50 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 16 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,862 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 142 | $190.39 | $27,035.38 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 15 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,987 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 73 | $190.33 | $13,894.09 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 14 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,129 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 5 | $190.27 | $951.35 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 13 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,202 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 144 | $190.02 | $27,362.88 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 12 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,207 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 144 | $189.24 | $27,250.56 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 11 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,351 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 8 | $189.18 | $1,513.44 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 10 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,495 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 73 | $189.01 | $13,797.73 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 9 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,503 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 127 | $188.26 | $23,909.02 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 8 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,576 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 130 | $187.35 | $24,355.50 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 7 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,703 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 137 | $187.08 | $25,629.96 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,833 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 124 | $186.22 | $23,091.28 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,970 F3 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 122 | $186.48 | $22,750.56 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,094 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 1 | $190.50 | $190.50 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,216 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 2,415 | $189.13 | $456,748.95 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,217 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 22:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 5,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-21-000097 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,632 F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2013 (right to buy) · Derivative | 10,834 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001735276-21-000081 · edgardoc.xml · derivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,832 Underlying: Common Stock · 10,834 shares Expires 2023-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 10,834 | $200.00 | $2,166,800.00 |
DisclosureSEC source: 0001735276-21-000081 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,215 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 10,834 | $63.00 | $682,542.00 |
DisclosureSEC source: 0001735276-21-000081 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 970 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-21-000051 · edgardoc.xml · derivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,368 Underlying: Common Stock · 970 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2013 (right to buy) · Derivative | 10,834 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001735276-21-000051 · edgardoc.xml · derivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,666 Underlying: Common Stock · 10,834 shares Expires 2023-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 14,708 | $175.00 | $2,573,900.00 |
DisclosureSEC source: 0001735276-21-000051 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,215 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 970 | $42.22 | $40,953.40 |
DisclosureSEC source: 0001735276-21-000051 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 10,834 | $63.00 | $682,542.00 |
DisclosureSEC source: 0001735276-21-000051 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:16 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $33.36 | $0.00 |
DisclosureSEC source: 0001179110-21-006458 · edgar.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2031-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2021 and is scheduled to vest in full on June 3, 2022. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 20:10 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $26.78 | $0.00 |
DisclosureSEC source: 0001179110-21-006138 · edgar.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-05-27 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. Read SEC document |
| April 21, 2021 Filed Apr 21, 2021 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 107 | $138.48 | $14,817.36 |
DisclosureSEC source: 0001735276-21-000041 · edgardoc.xml · nonDerivative · entry 11 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,119 F2 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on April 20, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. Read SEC document |
| April 21, 2021 Filed Apr 21, 2021 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 530 | $137.60 | $72,928.00 |
DisclosureSEC source: 0001735276-21-000041 · edgardoc.xml · nonDerivative · entry 10 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,226 F2 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on April 20, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. F10 · price: Sale prices ranged from $137.42 to $138.10. Read SEC document |
| April 21, 2021 Filed Apr 21, 2021 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,892 | $136.84 | $258,901.28 |
DisclosureSEC source: 0001735276-21-000041 · edgardoc.xml · nonDerivative · entry 9 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,756 F2 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on April 20, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. F9 · price: Sale prices ranged from $136.41 to $137.33. Read SEC document |
| April 21, 2021 Filed Apr 21, 2021 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 203 | $135.41 | $27,488.23 |
DisclosureSEC source: 0001735276-21-000041 · edgardoc.xml · nonDerivative · entry 8 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,648 F2 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on April 20, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. F8 · price: Sale prices ranged from $135.24 to $135.96. Read SEC document |
| April 20, 2021 Filed Apr 21, 2021 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 85 | $134.56 | $11,437.89 |
DisclosureSEC source: 0001735276-21-000041 · edgardoc.xml · nonDerivative · entry 7 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,851 F7 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 20, 2021 Filed Apr 21, 2021 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 2,266 | $131.75 | $298,545.50 |
DisclosureSEC source: 0001735276-21-000041 · edgardoc.xml · nonDerivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,936 F7 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 417 | $140.02 | $58,388.34 |
DisclosureSEC source: 0001735276-21-000041 · edgardoc.xml · nonDerivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,202 F2 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on April 20, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. F6 · price: Sale prices ranged from $139.72 to $140.18. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 622 | $138.64 | $86,234.08 |
DisclosureSEC source: 0001735276-21-000041 · edgardoc.xml · nonDerivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,619 F2 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on April 20, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. F5 · price: Sale prices ranged from $138.34 to $139.27. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 989 | $137.60 | $136,086.40 |
DisclosureSEC source: 0001735276-21-000041 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,241 F2 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on April 20, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. F4 · price: Sale prices ranged from $137.28 to $138.13. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,678 | $136.76 | $229,483.28 |
DisclosureSEC source: 0001735276-21-000041 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,230 F2 · kind: All sales reported on this Form 4, other than the sell-to-cover for taxes on April 20, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021. F3 · price: Sale prices ranged from $136.21 to $137.17. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 5,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-21-000041 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,908 F1 · kind: On February 26, 2020, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and one-third of the PSU award vested as of April 19, 2021. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 28,800 | $0.00 Strike: $151.59 | $0.00 |
DisclosureSEC source: 0001735276-21-000024 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,800 Underlying: Common Stock · 28,800 shares Expires 2031-02-23 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2020. The reporting person also received 15,437 performance stock units that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 92 | $152.53 | $14,032.76 |
DisclosureSEC source: 0001735276-21-000014 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,825 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 1,618 | $156.00 | $252,408.00 |
DisclosureSEC source: 0001735276-21-000014 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,917 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.